Madrigal Pharmaceuticals sustains strong commercial momentum with Rezdiffra, even amid new competition from semaglutide.

Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from ...

"Second quarter 2026 net sales were $364 million, representing year-over-year growth of 71%" and "we steadily add patients quarter-over-quarter" with "more than 49,000 active patients on Rezdiffra" at ...

Key Points Interested in Madrigal Pharmaceuticals, Inc.? Here are five stocks we like better. Rezdiffra sales rose 71% year ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. According to ...

On March 14, the Food and Drug Administration (FDA) signed off on Madrigal's therapy called Rezdiffra, which is the first approved drug that treats metabolic dysfunction-associated steatohepatitis ...